J&J Strikes Again in Spine
Executive Summary
J&J's aggressive moves in orthopedics has industry executives nervous, most recently about its purchases of artificial disk maker Waldemar Link and biomaterials expert Orquest. The Link valuation (J&J is paying $325 million upfront, plus earn-outs) isn't quite as high as some earlier orthopedics deals, but it is still comparatively substantial. With Link and Orquest under its roof, J&J is poised to assume market leadership in the traditional orthopedics markets and also in spine.
You may also be interested in...
Deal Statistics Quarterly, Q2 2003
In Vivo presents another installment of our quarterly reivew of dealmaking--in this case April-June 2003. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
Deal Statistics Quarterly, Q2 2003
In Vivo presents another installment of our quarterly reivew of dealmaking--in this case April-June 2003. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
Smith & Nephew and Centerpulse: Perfect Together
While the deal between Smith & Nephew and Centerpulse may feel like the product of recent events, most notably Centerpulse's troubles, a closer look reveals the complementary nature of the two companies, showing the merger would have made sense in any case.